| pubmed-article:7318760 | pubmed:abstractText | The authors present a synthesis of 277 observations collected in France from open studies of mianserin. The product has shown positive results in 65 per cent of the patients considered, based on the global clinical judgement of the prescriber at the beginning and the end of a 28 days open study. The data from Hamilton's scale for depression and Beck's Inventory, even though concerning a smaller number of patients, seem to provide similar results. The improvement appears from the first week, and seems to concern the overall depressive mood, anxiety, psychomotor inhibition, and sleep. The evaluation of the respective results for each target-symptom is made difficult due to the lack of precise data concerning the associated psychotropic drugs. Tolerance has generally been good; there have only been five drop-outs as a result of unpleasant side effects. | lld:pubmed |
